



PRELIMINARY PROGRAMME

SUNDAY, APRIL 7TH

15:00 – 15:30 **WELCOME**
Room 112

15:30 – 16:30 **FOKKO VAN DER WOUDE LECTURE**
Room 112

Chairs:

Luis Felipe Flores Suarez. *Primary Systemic Vasculitides Clinic. Instituto Nacional de Enfermedades Respiratorias, Mexico City, Mexico.*

David Jayne. *University of Cambridge, Cambridge, United Kingdom.*

The evolving landscape of vasculitis management: past, current, and emerging therapies

Speaker: Ronald Falk. *University of North Carolina, Chapel Hill, NC, United States.*

Fokko van der Woude Award announcement

16:30 – 16:45 **COFFEE BREAK**
Exhibition Area

16:45 – 17:45 **POSTER TOUR 1**
Poster Area

1A: Advances in treatment.
Posters TBC

1B: Diagnosis and classification.
Posters TBC

1C: Outcomes and predictors.
Posters TBC

17:45 – 18:45 **PLENARY SESSION**
Room 112

INNOVATIVE APPROACHES FOR VASCULITIS RESEARCHERS.

Chairs:

Alan Salama. *University College London, London, United Kingdom.*

Richard Kitching. *Monash University and Monash Health, Melbourne, Australia.*

Lecture: How immune/inflammatory cell atlas contribute to research in immune-mediated diseases?

Speaker: Juan C Nieto. *National Center for Genomic Analysis (CNAG), Barcelona, Spain*

Lecture: Kidney organoids: from development to human diseases.

Speaker: Nuria Montserrat. *Institute for Bioengineering of Catalonia (IBEC), Barcelona, Spain*

19:00 – 20:30 **Welcome Reception**
Banquet Hall

***Poster viewing: 15:00-18:45 -Poster Area**



MONDAY, APRIL 8TH

08:00 – 9:45
Room 112

PLENARY SESSION

CELLULAR AND MOLECULAR MECHANISMS OF DISEASE.

Chairs:

Peter Heeringa. University Medical Center Groningen, Groningen, The Netherlands.

Adrian Schreiber. Charité - Universitätsmedizin, Berlin, Berlin, Germany.

Abs 302. Regulatory T Cells Contribute to Downregulation of the Autoimmune Anti-MPO Response.

Speaker: Meghan Free. UNC-Chapel Hill, Chapel Hill, United States.

Abs 437. Manipulation of the gut microbiome protects from kidney inflammation and injury in experimental myeloperoxidase anti neutrophil cytoplasmic antibody vasculitis.

Speaker: Kim Maree O'Sullivan. Monash University, Melbourne, Australia.

Abs 397. Myeloperoxidase-specific IgM B cells in anti-neutrophil cytoplasmic antibody-associated vasculitis.

Speaker: Diane Van Der Woude. Leiden University Medical Center, Leiden, Netherlands.

Abs 54. CD19 CAR T cells mediate nephroprotective effects in a murine model of ANCA-induced crescentic glomerulonephritis.

Speaker: Dörte Lodka. Experimental and Clinical Research Center, Charité - Universitätsmedizin Berlin and Max Delbrück Center for Molecular Medicine in the Helmholtz Association, Berlin, Germany.

Abs 51. Effect of interleukin-17 in giant cell arteritis.

Speaker: Maxime Samson. Dijon University Hospital; Université Bourgogne Franche-Comté, INSERM, EFS BFC, UMR1098, RIGHT Interactions Greffon-Hôte-Tumeur/Ingénierie Cellulaire et Génique, Dijon, France.

Abs 423. Type I interferon pathway is upregulated in microscopic polyangiitis (vs granulomatosis with polyangiitis).

Speaker: Benoit Brilland. CHU Angers, Angers, France.

Abs 244. DNA repair antibody Deoxy Mab 1 inhibits neutrophil extracellular traps (NETs) and attenuates inflammation and kidney injury in experimental anti neutrophil cytoplasmic antibody vasculitis.

Speaker: Kim Maree O'Sullivan. Monash University, Melbourne, Australia.



09:45 – 10:30

COFFEE BREAK & **POSTER TOUR 2**

Poster &
Exhibition Area

2A: Advances in treatment.
Posters TBC

2B: Diagnosis and classification.
Posters TBC

2C: Outcomes and predictors.
Posters TBC

10:30 – 12:30
Room 112

PLENARY SESSION

ADVANCES IN TREATMENT (I)

Chairs:

Rona Smith. University of Cambridge, Cambridge, United Kingdom.

Bernhard Hellmich. University of Tübingen, Kirchheim-Teck, Germany.

Abs 84. A Randomized, Double-Blind, Placebo-Controlled Trial of Abatacept for the Treatment of Relapsing, Non-Severe, Granulomatosis with Polyangiitis.

Speaker: Carol Langford. Cleveland Clinic, Cleveland, United States.

Abs 180. A multicenter, randomized, controlled trial evaluating the effects of low-dose glucocorticoids compared to stopping glucocorticoids to maintain remission of granulomatosis with polyangiitis: The TAPIR trial.

Speaker: Peter Merkel. University of Pennsylvania, Philadelphia, United States.

Abs 292. The effect of plasma exchange on early renal improvement in patients with ANCA-associated vasculitis: a post-hoc analysis of the PEXIVAS trial.

Speaker: Balazs Odler. Medical University of Graz, Graz, Austria.

Abs 122. Innovative anti-pneumococcal vaccine strategies versus standard vaccination regimen in patients with ANCA-associated vasculitides receiving rituximab therapy: A Multicenter Randomized Controlled Trial (PNEUMOVAS).

Speaker: Benjamin Terrier. Cochin Hospital, Paris, France.

Abs 113. Safety of Avacopan in ANCA-Associated Vasculitis: Combined Data from Three Clinical Trials.

Speaker: Peter Merkel. University of Pennsylvania, Philadelphia, United States.

Abs 109. Report on Twelve Patients with Diffuse Alveolar Hemorrhage in the Phase 3 Trial of Avacopan for the Treatment of ANCA-Associated Vasculitis?

Speaker: Ulrich Specks. Mayo Clinic, Rochester, United States.



Lecture: Emerging cell therapies in the vasculitis field.

Speaker: Meghan Free. *UNC-Chapel Hill, Chapel Hill, United States.*

12:30 - 13:15
Room 113

INDUSTRY SYMPOSIUM

12:30 – 13:30
Exhibition Area

LUNCH

13:30 – 15:00
Room 112

BREAKOUT SESSION

GENETIC AND ENVIRONMENT CONDITIONINGS OF VASCULITIS

Chairs:

Neil Basu. *University of Glasgow, Glasgow, United Kingdom.*

Peter Grayson. *National Institutes of Health, Bethesda, United States.*

Lecture: Potential climate determinants of different types of vasculitis.

Speaker: Xavier Rodó. *Climate and Health Program, ISGlobal, Barcelona, Spain.*

Abs 125. Association between infections and the onset of giant-cell arteritis and polymyalgia rheumatica: a nested case control Study from the French E3N-EPIC cohort study.

Speaker: Lucas Pacoureaux. *Université Paris-Saclay, UVSQ, Inserm, Gustave Roussy, CESP, Villejuif, France.*

Abs 58. Genetic susceptibility to patterns of arterial involvement in Takayasu arteritis.

Speaker: Amr H. Sawalha. *University of Pittsburgh, Pittsburgh, United States.*

Abs 500. A large-scale genome-wide association study of polymyalgia rheumatica to identify disease-specific loci.

Speaker: Dimitria-Ilektra Lerou. *University of Leeds, UK, Leeds, United Kingdom.*

13:30 – 15:00
Room 113

BREAKOUT SESSION

TRANSCRIPTOMIC APPROACHES TO THE STUDY OF SYSTEMIC VASCULITIS.

Chairs:

Ann Morgan. *University of Leeds, Leeds, United Kingdom.*

Dominic Ciavatta. *University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States.*

Lecture: Spatial transcriptomics in glomerular diseases.

Speaker: Renate Kain. *Medical University Vienna, Vienna, Austria.*



Abs 324. Multi-level transcriptomic profiling of temporal artery tissue reveals novel pathways involved in the immune process and vascular remodelling in giant cell arteritis.

Speaker: Michael Zulcinski. University of Leeds, Leeds, United Kingdom.

Abs 70. Single-cell RNA-sequencing exposes biological differences in giant cell arteritis lesions between disease relapse and disease onset

Speaker: Maira Karabayas. University of Aberdeen, Aberdeen, United Kingdom.

Abs 229. Genes deregulated in giant cell arteritis by high-throughput expression profiling in temporal artery biopsies.

Speaker: Stefania Croci. AUSL-IRCCS di Reggio Emilia, Reggio Emilia, Italy.

13:30 – 15:00
Room 118+119

BREAKOUT SESSION

MANAGEMENT OF SPECIFIC SITUATIONS.

Chairs:

Ahmet Gul. Istanbul University, Istanbul, Turkey.

Carol Langford. Cleveland Clinic, Cleveland, United States.

Abs 452. Abdominal Surgical Interventions Among Patients with Gastrointestinal Involvement of Behçet Syndrome.

Speaker: Gulen Hatemi. Istanbul University-Cerrahpasa,, Istanbul, Turkey.

Abs 15. Reproductive Outcomes for Women with Vasculitis.

Speaker: Catherine Sims. Duke University, Durham, United States.

Abs 16. Exploring Reproductive Experiences with Women Enrolled in the Vasculitis Pregnancy Registry.

Speaker: Catherine Sims. Duke University, Durham, United States.

Abs 410. Evaluating the role of immunosuppression in ANCA+ve and idiopathic subglottic stenosis.

Speaker: Guy Beshetrit. Imperial College London, London, United Kingdom.

Abs 152. Subglottic stenosis in patients with granulomatosis with polyangiitis – the clinical value of an airway biopsy.

Speaker: Louise Linde. RIGSHOSPITALET, Copenhagen, Denmark.

15:00 – 16:20
Room 112

BREAKOUT SESSION

BIOMARKERS OF CLINICAL INTEREST.

Chairs:

Mark Little. Trinity College Dublin, Dublin, Ireland.

Elizabeth Brouwer. University Medical Center Groningen, Groningen, The Netherlands.



Abs 428. Autoantibody profiling to identify novel candidate biomarkers in ANCA associated vasculitis.

Speaker: *Elisa Pin. KTH Royal Institute of Technology, SciLifeLab, Stockholm, Sweden.*

Abs 139. Torque teno virus as a potential biomarker for assessment of immunocompetence in patients with ANCA-associated vasculitis.

Speaker: *Balasz Odler. Medical University of Graz, Graz, Austria.*

Abs 326. A germline genetic biomarker predicts treatment response to tocilizumab in giant cell arteritis.

Speaker: *Peter Grayson. National Institutes of Health, Bethesda, United States.*

Abs 261. Serial measures of usCD163 predict kidney failure in AAV-GN

Speaker: *Sinead Stoneman. University College Cork, Cork, Republic of Ireland.*

Abs 132. Plasma and urine metabolomic profiles reveal potential biomarkers in MPO-ANCA-GN.

Speaker: *Yong Zhong. Xiangya Hospital, Central South University, Changsha, China.*

Abs 115. Circulating Immune Profile in Granulomatosis with Polyangiitis Reveals Distinct Patterns Related to Disease Activity.

Speaker: *Nanthicha Inrueangsri. University Medical Center Groningen, Groningen, Netherlands.*

**15:00 – 16:20
Room 113**

BREAKOUT SESSION

ADVANCES IN POLYMYALGIA RHEUMATICA

Chairs:

Sarah Mackie. *University of Leeds, Leeds, United Kingdom.*

Carlo Salvarani. *Azienda USL-IRCCS di Reggio Emilia, Reggio Emilia, Italy.*

Lecture: Imaging findings in polymyalgia rheumatica.

Online Speaker: *Claire Owen. Austin Health, Melbourne, VIC 3081, Australia.*

Lecture: Advances in the treatment of Polymyalgia rheumatica.

Speaker: *Christian Dejaco. Hospital of Bruneck, Bruneck, Italy.*

Lecture: How and when to look for occult giant-cell arteritis in patients with polymyalgia rheumatica.

Speaker: *Daniel Blockmans. University Hospitals Leuven, Leuven, Belgium.*



15:00 – 16:20
Room 118+119

BREAKOUT SESSION

OPTIMIZING NEW TREATMENTS.

Chairs:

Rachel Jones. *Cambridge University Hospitals, Cambridge, United Kingdom.*

Charles Pusey. *Imperial College London, London, United Kingdom.*

Abs 184. Avacopan for the treatment of ANCA-associated vasculitis: a multicenter prospective, real-life, study on efficacy, safety and impact on quality of life.

Speaker: Elena Treppo. *University of Udine, Udine, Italy.*

Abs 499. A UK parallel cohort study on renal ANCA-associated vasculitis outcomes for avacopan exposed and matched unexposed cohorts.

Speaker: Lucy Frances. *Cambridge University Hospital, Cambridge, United Kingdom.*

Abs 307. Avacopan in combination with rituximab and low-dose cyclophosphamide for treatment of severe ANCA-associated glomerulonephritis.

Speaker: Amrita Dhutia. *Imperial College London, London, United Kingdom.*

Abs 170. Safety and efficacy of avacopan in patients 65 years and older with ANCA-associated vasculitis.

Speaker: Sebastian Sattui. *University of Pittsburgh, Pittsburgh, United States.*

Abs 496. Anti-IL-5 receptor therapy with benralizumab in the management of eosinophilic granulomatosis with polyangiitis (EGPA).

Speaker: Allyson Egan. *Vasculitis & Lupus Clinic, Cambridge University Hospital, Cambridge, United Kingdom.*

Abs 379. Comparative efficacy of mepolizumab 100 mg, mepolizumab 300 mg and benralizumab 30 mg in eosinophilic granulomatosis with polyangiitis.

Speaker: Marta Codirezzi. *University of Padua, Padua, Italy.*

16:20 – 16:40

COFFEE BREAK

16:40 – 17:40
Room 112

DEBATE

SHOULD GLUCOCORTICOID DISCONTINUATION AS IN CLINICAL TRIALS BE A THERAPEUTIC TARGET IN REAL LIFE?

Chairs:

Rona Smith. *University of Cambridge, Cambridge, United Kingdom.*

Peter Merkel. *University of Pennsylvania, Philadelphia, United States.*



Viewpoint 1. Speaker: Sebastian Unizony. *Mass General Hospital – Harvard Medical School, Boston, USA.*

Viewpoint 2. Speaker: Benjamin Terrier. *Cochin Hospital, Paris, France.*

**16:40 – 17:40
Room 113**

DEBATE

DOES PLASMA EXCHANGE HAVE A ROLE IN ANCA-ASSOCIATED VASCULITIS?

Chairs:

Marta Casal Moura. *Mayo Clinic, Rochester, Minnesota, United States.*

David Jayne. *University of Cambridge, Cambridge, United Kingdom.*

Viewpoint 1. Speaker: Michael Walsh. *McMaster University, Hamilton, Canada.*

Viewpoint 2. Speaker: Wladimir Szpirt. *Copenhagen University Hospital, Copenhagen, Denmark.*

**16:40 – 17:40
Room 118+119**

SMALL WORKSHOP

CHOOSING ADJUVANT THERAPY (CONVENTIONAL OR TARGETED) IN TAKAYASU ARTERITIS

Leaders:

Haner Direskeneli. *Marmara University, Istanbul, Turkey.*

David Saadoun. *Pitié-Salpêtrière University Hospital, Paris, France.*

Carol Langford. *Cleveland Clinic, Cleveland, United States*

**17:40 – 18:40
Room 112**

CASE REPORT AND PANEL DISCUSSION.

Panel:

Elizabeth Brouwer. *University Medical Center Groningen, Groningen, The Netherlands.*

Roser Solans-Laque. *Hospital General Vall d'Hebron, Barcelona, Spain.*

Michael Clarkson. *Cork University Hospital, Cork, Ireland.*

Abs 305. ANCA associated vasculitis (AAV)-phenotype and ANCA positivity in monogenic lupus secondary to DNASE1L3 mutations: report of a case and review of the literature.

Speaker: Giulia Palazzini. *University of Firenze, Firenze, Italy.*

Abs 177. When you are told your 34-year old patient with Takayasu's disease has metastases.

Speaker: Irene Carrión Barberà. *Hospital del Mar, Barcelona, Spain.*

Abs 257. A novel role for obinutuzumab in a patient with relapsing PR3 ANCA-associated vasculitis and anti-GBM disease.

Speaker: Tariq Farra. *Royal Infirmary of Edinburgh, Edinburgh, United Kingdom.*



Abs 449. Bilateral renal infarcts as a manifestation of Granulomatous Eosinophilic Polyangiitis.

Speaker: Pedro Lisboa-Gonçalves. Centro Hospitalar Universitário São João, Porto, Portugal.

Abs 507. Acrocyanosis After Immunotherapy: Vasculitis or Vasculopathy? A New Iatrogenic Disease.

Speaker: Jamal Shahin. University of British Columbia, Vancouver, Canada.

**17:40 – 18:40
Room 113**

DEBATE

SHOULD TOCILIZUMAB BE USED IN EVERY PATIENT WITH GIANT-CELL ARTERITIS?

Chairs:

Maxime Samson. Dijon University Hospital, Dijon, France.

Robert Spiera. Weill Cornell Medicine, New York, United States.

Viewpoint 1. Speaker: Philip Seo. Johns Hopkins University, Baltimore, MD, United States.

Viewpoint 2. Speaker: Bernhard Hellmich. University of Tübingen, Kirchheim-Teck, Germany.

**17:40 – 18:40
Room 118+119**

SMALL WORKSHOP

DIFFERENCES IN GUIDELINES (ACR/EULAR/KADIGO/CANVASC/JAPANESE) FOR THE TREATMENT OF AAV: IMPLICATIONS FOR CLINICAL PRACTICE

Leaders:

Marta Casal Moura. Mayo Clinic, Rochester, Minnesota, United States.

Duvuru Geetha. Johns Hopkins University, Baltimore, United States.

Annette Brunchfeld. Linköping University/Karolinska Institutet, Huddinge, Sweden.

Christian Pagnoux. Mount Sinai Hospital, Toronto, Canada.

Toshiko Ito-hara. Kyoto Prefectural University of Medicine, Kyoto, Japan.

***Poster viewing: 08:00-18:30 - Poster Area**



TUESDAY, APRIL 9TH

08:00 – 9:45
Room 112

PLENARY SESSION

EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS AND HYPEREOSINOPHILIC DISEASES

Chairs:

Julia Holle. *Rheumazentrum Schleswig-Holstein Mitte, Neumünster, Germany.*

Augusto Vaglio. *University of Florence, Firenze, Italy.*

Lecture: Advances and translational impact of eosinophil biology.

Speaker: Paneez Khoury. *National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, United States.*

Abs 274. Benralizumab vs Mepolizumab in the Treatment of Eosinophilic Granulomatosis with Polyangiitis.

Speaker: Michael E. Wechsler. *National Jewish Health, Denver, United States.*

Abs 282. Complete Remission in Eosinophilic Granulomatosis with Polyangiitis (EGPA) in the MANDARA Trial of Benralizumab vs Mepolizumab.

Speaker: Michael E. Wechsler. *National Jewish Health, Denver, United States.*

Abs 96. Mepolizumab vs Benralizumab: a European real-life retrospective multicentre study.

Speaker: Irene Mattioli. *University of Florence, Florence, Italy.*

Abs 490. Investigating the impact of Anti-IL5 therapy in eosinophilic granulomatosis with polyangiitis (EGPA); a longitudinal perspective for three years and beyond.

Speaker: Allyson Egan. *Vasculitis and Lupus Clinic, Cambridge University Hospital, Cambridge, United Kingdom.*

Abs 296. Gene expression profile of CD4+ T cells is modified in eosinophilic granulomatosis with polyangiitis (EGPA).

Speaker: Nuria Farran. *IDIBAPS, Hospital Clinic (HC), University of Barcelona (UB), Barcelona, Spain.*

09:45 – 10:30

COFFEE BREAK & POSTER TOUR 3

Poster &
Exhibition Area

3A: Mechanisms of Disease.

Posters TBC

3B: Clinical epidemiology and observational studies.

Posters TBC



3C: Outcomes and predictors.

Posters TBC

10:30 – 12:30
Room 112

PLENARY SESSION

CLINICALLY RELEVANT OUTCOMES.

Chairs:

Luís F Quintana. Hospital Clinic Barcelona, Barcelona, Spain.

Fernando C Fervenza. Mayo Clinic, Rochester, Minnesota, United States.

Abs 297. Assessing the predictive role of monitoring creatinine, hematuria, and proteinuria for renal outcomes.

Speaker: Beatriz Sánchez Álamo. Nephrology Department, Hospital Universitario del Sureste, Madrid, Spain.

Abs 396. Prediction of Recovery of Kidney Function in Severe ANCA Glomerulonephritis.

Speaker: Silke Brix. University Manchester, Manchester, United Kingdom.

Abs 426. Outcomes after kidney transplantation in anti-Glomerular basement membrane disease.

Speaker: Benoit Brilland. CHU Angers, Angers, France.

Abs 25. Agglomerative hierarchical cluster analysis identifies two clusters of Takayasu arteritis based on clinical phenotype which predict angiographic findings and mortality.

Speaker: Misra Durga Prasanna. Sanjay Gandhi Postgraduate Institute of Medical Sciences (SGPGIMS), Lucknow, India.

Abs 365. Outcomes of Intensive Care Patients with Acute Small-Vessel Vasculitis: A 23-year Single-Centre Experience.

Speaker: Arden Dierker Viik. School of Clinical Medicine, University of Cambridge, Cambridge, United Kingdom.

Abs 174. Frailty and associated outcomes in patients with vasculitis.

Speaker: Sebastian Sattui. University of Pittsburgh, Pittsburgh, United States.

Abs 375. RETRACE-Clustering Creatinine Trajectory and Baseline Features for Predicting End Stage Kidney Disease.

Speaker: Jamsheela Nazeer. Trinity College Dublin, Dublin, India.

Abs 425. Outcomes after kidney transplantation in ANCA-associated vasculitis.

Speaker: Benoit Brilland. CHU Angers, Angers, France.

12:30 - 13:15
Room 113

INDUSTRY SYMPOSIUM



12:30 – 13:30
Exhibition Area

LUNCH

13:30 – 15:00
Room 112

BREAKOUT SESSION

DIAGNOSIS AND CLASSIFICATION OF VASCULITIS.

Chairs:

Cristina Ponte. Hospital de Santa Maria, Centro Hospitalar Universitário Lisboa Norte, Lisbon, Portugal.

Ravi Suppiah. Te Whatu Ora - Health New Zealand, Auckland, New Zealand

Abs 477. Application of the EULAR/PRINTO/PRES (Ankara 2008) Classification Criteria for IgA Vasculitis in Adults.

Speaker: Yagmur Bayindir. Hacettepe University Children's Hospital, Ankara, Turkey.

Abs 253. Data driven subclassification of ANCA associated vasculitis – model-based clustering of the FAIRVASC cohort.

Speaker: Karl Gisslander. Lund University, Lund, Sweden.

Abs 266. Application of the 2022 ACR/EULAR classification criteria in a cohort of 152 patients with microscopic polyangiitis and granulomatosis with polyangiitis.

Speaker: João Fernandes-Serodio. Hospital Fernando Fonseca, Amadora, Portugal.

Abs 254. Using a standardised biopsy evaluation increases the impact of temporal artery biopsy in GCA.

Speaker: Ömer Karadağ. Turkish Vasculitis Study Group (TRVaS), Ankara, Turkey.

Abs 417. How giant cell arteritis ultrasound diagnostics may profit from phantom research.

Speaker: Hanneke Maan. Hospital Group Twente, Almelo, Netherlands.

Abs 162. Diagnostic performance of short and long [18F]FDG-PET acquisition in giant cell arteritis.

Speaker: Marieke van Niewland. Hospital Group Twente, Almelo, Netherlands.

13:30 – 15:00
Room 113

BREAKOUT SESSION

CELLULAR AND MOLECULAR MECHANISMS OF DISEASE (II).

Chairs:

Kazuo Suzuki. Chiba University, Chiba, Japan.

Mark Little. Trinity College Dublin, Dublin, Ireland.



Abs 38. Human MPO-ANCA induces crescentic glomerulonephritis in mice expressing human MPO and FcγRIIa.

Speaker: Minh Huan Dang. Monash Medical Centre, Clayton, Victoria, Australia.

Abs 148. The sequential carbonyl derivatives and hydrazones adduct formation on myeloperoxidase contribute to development of auto-antigenicity.

Speaker: Gang Xi. University of North Carolina at Chapel Hill, UNC Kidney Center, Chapel Hill, United States.

Abs 381. Isolation and profiling of auto-antigen specific B cells in MPO-ANCA vasculitis.

Speaker: Dhruvi Chen. UNC, Chapel Hill, United States.

Abs 89. Unraveling the impact of TSST-1 on T and B cell response in granulomatosis with polyangiitis: Insights into disease pathogenesis and progression

Speaker: Hang Liao. University Medical Center Groningen, Groningen, Netherlands.

Abs 13. Bruton's tyrosine kinase is a possible therapeutic target in MPO-ANCA associated vasculitis.

Speaker: Akihiro Ishizu. Hokkaido University, Sapporo, Japan.

13:30 – 15:00
Room 118+119

BREAKOUT SESSION
PEDIATRIC VASCULITIS.

Chairs:

Seza Ozen. Hacettepe University, Ankara, Turkey.

Jordi Anton. Hospital maternoinfantil Sant Joan de Deu, Barcelona, Spain.

Lecture: Hypoxia signaling and vasculitis: connecting HIFs with coronary damage in Kawasaki disease.

Speaker: Silvia Martin Puig. National Center for Cardiovascular Research, Madrid, Spain.

Abs 419. ANCA-Associated Vasculitis at Children's Hospital Colorado: Pediatric Patient Characteristics, Clinical Course, and Outcomes.

Speaker: Jessica Bloom. University of Colorado, Denver, United States.

Abs 164. Clinical course of pediatric-onset Behçet's Disease in young adulthood.

Speaker: Fatma Aliva Onez. Marmara University School of Medicine, Istanbul, Turkey.



Abs 260. HLA class I and II gene polymorphisms in childhood IgA vasculitis.

Speaker: Marija Jelusic. University of Zagreb School of Medicine, University Hospital Centre Zagreb, Zagreb, Croatia.

Abs 420. Kidney transplantation in childhood-onset ANCA-associated vasculitis: outcomes of a multicentre cohort.

Speaker: Giorgio Trivioli. Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom.

**15:00 – 16:20
Room 112**

BREAKOUT SESSION

ADVANCES IN TREATMENT (II).

Chairs:

Marten Segelmark. Lund Univeristy, Lund, Sweden.

Montserrat E Díaz. Fundació Puigverd, Barcelona, Spain.

Abs 112. Remission, Glucocorticoid Toxicity, Health-Related Quality of Life, and Safety Outcomes in Patients with ANCA-Associated Vasculitis with Kidney Involvement Treated with Avacopan.

Speaker: Peter A. Merkel. University of Pennsylvania, Philadelphia, United States.

Abs 351. Real-life Use of the PEXIVAS Reduced-dose Glucocorticoid Regimen in Granulomatosis with Polyangiitis and Microscopic Polyangiitis.

Speaker: Benjamin Terrier. AP-HP Cochin Hospital, Paris, France.

Abs 431. Kinetics of auto-antibodies removal with immunoadsorption or plasma exchange: results of the CINEVAS study.

Speaker: Benjamin Terrier. AP-HP Cochin Hospital, Paris, France.

Lecture: Emerging targeted therapies in vasculitis.

Speaker: David Jayne. University of Cambridge, Cambridge, United Kingdom.

**15:00 – 16:20
Room 113**

BREAKOUT SESSION

OUTCOME PREDICTORS.

Chairs:

Dimitrios Vasilopoulos. National and Kapodistrian University of Athens, Athens, Greece.

Duvuru Geetha. Johns Hopkins University, Baltimore, United States.

Abs 154. Albuminuria after induction treatment and kidney prognosis in ANCA-associated glomerulonephritis.

Speaker: Aglaia Chalkia. University of Cambridge, Department of Medicine, Cambridge, United Kingdom.



Abs 130. Frequency and the effects of spondylarthritis spectrum disorders on the clinical course and management of Takayasu arteritis.

Speaker: *Fatma Alibaz-Oner. Marmara University, Istanbul, Turkey.*

Abs 286. ABO blood groups and increased risk for vascular involvement in patients with Behçet disease.

Speaker: *Erden Bektas. Istanbul University, Istanbul, Turkey.*

Abs 189. Renal prognosis of dialysis-dependent patients at baseline in ANCA-associated vasculitis.

Speaker: *Benjamin Terrier. Hôpital Cochin, Paris, France.*

Abs 349. The prognostic value of presenting features on the short and long –term prognosis of giant-cell arteritis patients: data for the Italian Society of Rheumatology group.

Speaker: *Alessandro Tomelleri. IRCCS San Raffaele Hospital, Milan, Italy.*

15:00 – 16:20
Room 118+119

BREAKOUT SESSION

OTHER FORMS OF VASCULITIS.

Chairs:

Kenneth Warrington. *Mayo Clinic, Rochester, United States.*

Tanaz Kermani. *University of California Los Angeles, Los Angeles, California, United States.*

Lecture: Update on IgG4-related disease.

Speaker: *John H Stone. Harvard Medical School, Boston, Massachusetts, United States.*

Abs 372. Methotrexate as a steroid-sparing agent in chronic periaortitis (idiopathic retroperitoneal fibrosis): a multicentre randomised clinical trial.

Speaker: *Francesco Peyronel. University of Firenze, Firenze, Italy.*

Abs 328. Histopathological evaluation of IgG4-RD using the 2019 ACR/EULAR scoring system.

Speaker: *Jet Vedder-Hobbelink. University Medical Center Groninge, Groningen, Netherlands.*

Abs 413. Rituximab in adult-onset IgA Vasculitis and crescentic IgA Nephropathy. A multicentre study

Speaker: *Giorgio Trivioli. Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom.*

16:20 – 16:40

COFFEE BREAK



16:40 – 17:40
Room 112

DEBATE

ANCA NEGATIVE EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS (EGPA): A VARIANT OF EGPA OR CLOSER TO THE IDIOPATHIC HYPEREOSINOPHILIC SYNDROME?

Chairs:

Julia Holle. Rheumazentrum Schleswig-Holstein Mitte, Neumünster, Germany.

Allyson Egan. Vasculitis and Lupus Clinic, Cambridge University Hospital, Cambridge, United Kingdom.

Viewpoint 1. Speaker: Paneez Khoury. National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, United States.

Viewpoint 2. Speaker: Florence Roufousse. Hôpital Erasme, Université Libre de Bruxelles, Brussels, Belgium.

16:40 – 17:40
Room 113

DEBATE

DOES IDIOPATHIC POLYARTERITIS NODOSA EXIST?

Chairs:

Xavier Puechal. Hôpital Cochin, Université Paris Cité, Paris, France.

Chetan Mukhtyar. Norfolk and Norwich University Hospitals NHS Foundation Trust, Norwich, United Kingdom

Viewpoint 1. Speaker: Omer Karadag. Faculty of Medicine, Hacettepe University, Ankara, Turkey.

Viewpoint 2. Speaker: Richard Watts. Norwich Medical School, Norwich, United Kingdom.

16:40 – 17:40
Room 118+119

TRAINEE CAREER ORIENTATION SESSION

PURSUING AN ACADEMIC CAREER IN VASCULITIS

Chairs:

Elizabeth Brouwer. University Medical Center Groningen, Groningen, The Netherlands.

Ann Morgan. University of Leeds, Leeds, United Kingdom.

Lecture: The Clinician Scientist Career: Challenges and opportunities.

Speaker: Jatin Vyas. Massachusetts General Hospital and Harvard Medical School, Boston, MA, United States.

Panel:

- **Senior Clinician scientist: Alan Salama.** University College London, London, United Kingdom.
- **Mid-career clinician scientist: Maxime Samson.** Dijon University Hospital, Dijon, France.
- **Mid-career clinician scientist: Maria Sandovici.** University of Groningen, University Medical Center Groningen, Groningen, Netherlands.



16:40 – 17:40
Room 120

SMALL WORKSHOP

DIAGNOSIS, ASSESSMENT AND MANAGEMENT OF MONOGENIC VASCULITIS

Leaders:

Seza Ozen. Hacettepe University, Ankara, Turkey.

Peter Grayson. National Institutes of Health, Bethesda, United States.

Juan Ignacio Arostegui. Hospital Clinic Barcelona, Barcelona, Spain.

17:40 – 18:40
Room 112

CASE REPORTS OF SPECIAL INTEREST

Panel:

Allyson Egan. Vasculitis & Lupus Clinic, Cambridge University Hospital, Cambridge, United Kingdom.

Juan Ignacio Arostegui. Hospital Clinic Barcelona, Barcelona, Spain.

Carol Langford. Cleveland Clinic, Cleveland, United States

Abs 193. Giant cell arteritis in patients with systemic sclerosis: a case series.

Speaker: Max Guarda. Mayo Clinic, Rochester, MN, United States.

Abs 215. Managing relapse and progressive multifocal leukoencephalopathy in PR3 ANCA-positive vasculitis: the balance between immunosuppression and immunocompetence.

Speaker: Giorgio Trivioli. Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom.

Abs 268. VEXAS masquerading as Granulomatosis with Polyangiitis (GPA).

Speaker: Arslan Ather. Peterborough City Hospital, Peterborough, United Kingdom.

Abs 374. Paraneoplastic MPO+ ANCA vasculitis in Chronic Lymphocytic Leukemia.

Speaker: Katherine Jicha. UNC Kidney Center, Chapel Hill, United States.

Abs 219. A case of a puerperal granulomatosis with polyangiitis relapse.

Speaker: Cliona Cowhig. Cork University Hospital, Cork, Republic of Ireland.

17:40 – 18:40
Room 113

DEBATE

BIOPSY OR IMAGING IN THE DIAGNOSIS OF GIANT-CELL ARTERITIS?

Chairs:

Kenneth Warrington. Mayo Clinic, Rochester, United States.

Eugenio de Miguel. Hospital Universitario La Paz, Madrid, Spain.



Viewpoint 1. Speaker: Wolfgang Schmidt. Immanuel Krankenhaus Berlin, Medical Center for Rheumatology Berlin-Buch, Berlin, Germany

Viewpoint 2. Speaker: Maria C Cid. Hospital Clínic de Barcelona, Barcelona, Spain.

17:40 – 18:40
Room 118+119

TRAINEE SESSION

3 MIN PRESENTATION OF RESEARCH PROJECTS

Panel:

Neeraj Dhaun. University of Edinburgh, Royal Infirmary of Edinburgh, Centre for Cardiovascular Science, Edinburgh, United Kingdom.

Peter Heeringa. University Medical Center Groningen, Groningen, The Netherlands.

Aladdin Mohammad. Lund University, Lund, Sweden.

Maxime Samson. Dijon University Hospital, Dijon, France.

Projects TBC

17:40 – 18:40
Room 120

SMALL WORKSHOP

PREDICTORS OF RELAPSE IN AAV

Leaders:

Mark Little. Trinity College Dublin, Dublin, Ireland.

Irmgard Neumann. Vasculitis, Vienna, Austria and Immunologiezentrum Zurich, Switzerland.

Silke Brix. Manchester University Hospitals NHS Foundation Trust, Manchester, United Kingdom.

Andreas Kronbichler. Medical University Innsbruck, Innsbruck, Austria.

***Poster viewing: 08:00-18:30 -Poster Area**



WEDNESDAY, APRIL 10TH

08:00 – 09:45
Room 112

PLENARY SESSION

END-ORGAN DAMAGE AND REPAIR

Chairs:

Jacobo Sellares. Hospital Clinic Barcelona, Barcelona, Spain.

Juan C Nieto. National Center for Genomic Analysis (CNAG), Barcelona, Spain

Lecture: Mechanisms of organ fibrosis.

Speaker: Robert Lafyatis. University of Pittsburgh, Pittsburgh, Pennsylvania.

Abs 155. Long-term Observational Study of Interstitial Lung Disease in ANCA-Associated Vasculitis: European Multicentre Study.

Speaker: Aglaia Chalkia. University of Cambridge, Department of Medicine, Cambridge, United Kingdom.

Abs 32. Neutrophil proteases and free fatty acids mediate giant-cell and granuloma formation in granulomatosis with polyangiitis: implications for therapy.

Speaker: Alan Salama. Royal Free Hospital And UCL Kidney and Bladder Health, London, United Kingdom.

Lecture: Lung fibrosis in ANCA-associated vasculitis: clinical, imaging and therapeutic perspective.

Speaker: Ulrich Specks. Mayo Clinic Rochester, Rochester, Minnesota, United States.

09:45 – 10:30
Poster &
Exhibition Area

COFFEE BREAK & POSTER TOUR 4

10:30 – 12:30
Room 112

PLENARY SESSION

ACR-EULAR CRITERIA FOR CLINICAL RESPONSE IN ANCA-ASSOCIATED VASCULITIS.

Panel:

Kaitlin A Quinn. National Institutes of Arthritis and Musculoskeletal and Skin Diseases, Bethesda, Maryland.

Sara Monti. University of Pavia, Pavia, Italy.

Gunnar Tomasson. University of Iceland, Reykjavik, Iceland.

Peter Merkel. University of Pennsylvania, Philadelphia, United States.

Introduction and Rationale for Developing Criteria for Response for ANCA-Associated Vasculitis

Results from the systematic literature review and Delphi exercise



Methodology and results of data-driven steps to derive the ACR-EULAR Criteria for Clinical Response in ANCA-Associated Vasculitis

The ACR-EULAR Criteria for Clinical Response in ANCA-Associated Vasculitis: Final criteria and use in clinical trials

Questions and Answers

12:30 – 13:30
Exhibition Area

LUNCH

13:30 – 15:00
Room 112

BREAKOUT SESSION

IMAGING IN DISEASE ASSESSMENT.

Chairs:

Wolfgang Schmidt. *Immanuel Krankenhaus Berlin, Medical Center for Rheumatology Berlin-Buch, Berlin, Germany.*

Cristina Ponte. *Hospital de Santa Maria, Centro Hospitalar Universitário Lisboa Norte, Lisbon, Portugal.*

Daniel Blockmans. *University Hospitals Leuven, Leuven, Belgium.*

Lecture: Emerging radiotracers for vascular imaging.

Speaker: Jason Tarkin. *University of Cambridge, Cambridge, United Kingdom.*

Abs 74. Association of extent of vascular inflammation on cranial MRI with visual complications in giant cell arteritis.

Speaker: Rennie Rhee. *University of Pennsylvania, Philadelphia, United States.*

Abs 352. Imaging and clinical predictors of outcomes in chronic periaortitis.

Speaker: Milena Bond. *Hospital of Brunico, Brunico, Italy.*

Abs 376. Predictors of disease relapse in ANCA-associated vasculitis with radiomics of lung nodules/masses.

Speaker: Samuel Falde. *Mayo Clinic, Rochester, United States.*

Abs 367. Use of FDG-PET to Monitor Disease Activity in Patients with Giant Cell Arteritis on Tocilizumab.

Speaker: Kaitlin Quinn. *NIAMS, National Institutes of Health, Bethesda, United States.*

Abs 342. Comparing Clinical and Imaging assessment in Three Takayasu's Arteritis Cohorts by using the Takayasu's Arteritis Disease Activity Index.

Speaker: Chiara Marvisi. *Azienda USL-IRCCS of Reggio Emilia, Reggio Emilia, Italy.*



Abs 107. Protocolised ultrasonography led pathway has a high sensitivity for diagnosis of primary large vessel vasculitis.

Speaker: Chetan Mukhtyar. Norfolk and Norwich University Hospitals NHS Foundation Trust, Norwich, United Kingdom

13:30 – 14:30
Room 113

BREAKOUT SESSION
CO-MORBIDITIES

Chairs:

Joanna Robson. UWE Bristol, Bristol, United Kingdom.

Thomas Neumann. Cantonal Hospital, St. Gallen, Switzerland.

Abs 337. Comprehensive evaluation of long-term cardiovascular comorbidities among patients with AAV.

Speaker: Beatriz Sánchez Álamo. Hospital Universitario del Sureste, Madrid, Spain.

Abs 8. Prevalence, predictors, and prognosis of serious infections in Takayasu arteritis – a cohort study.

Speaker: Durga Prasanna Misra. Sanjay Gandhi Postgraduate Institute of Medical Sciences (SGPGIMS), Lucknow, India.

Abs 178. Hypogammaglobulinemia in patients with ANCA-associated vasculitis, treated with Rituximab.

Speaker: Jens Rathmann. Lund University, Rheumatology, Lund, Sweden.

Abs 327. Hospitalization rates and features of a large multicentric cohort of patients with ANCA-associated vasculitis.

Speaker: Alvise Berti. CISMED - University of Trento, Trento, Italy.

15:00 – 15:30
Room 112

CLOSING REMARKS

***Poster viewing: 08:00-16:00 -Poster Area**



LEARNING OBJECTIVES

Participants will gain knowledge in various state-of-the-art and cutting-edge aspects of vasculitis and related diseases, including clinical and translational aspects.

- Innovative approaches in research
- Novelties in mechanistic pathways
- Advances in classification and diagnosis
- Advances in imaging
- Advances in treatment and treatment tailoring to different clinical settings
- Emerging treatments
- Advances in the prevention and management of co-morbidities
- Biomarkers of clinical significance
- Advances in defining response criteria for clinical trials and clinical studies
- Advances in prediction of clinically relevant outcomes
- Objective approach and critical thinking regarding controversial aspects
- Appraisal of the potential of patient powered research
- Potential of collaborative networks in rare diseases such as vasculitis.

Attendees will be actively engage in discussions with vasculitis world leaders in small workshops and complex clinical case discussion sessions and debates. Moreover they will have a mentoring session about how to pursuit a career in academic medicine in the field, particularly focusing on the clinician scientist track.

After the difficult constrictions of the Covid 19 pandemic we expect this fully face-to-face meeting to provide a long-desired opportunity to discuss state of the art management of vasculitis and to share new information to understand mechanisms of disease and to improve patient care. Interchanging ideas and experiences, expanding networks and collaboration, as well as fostering inspiration and motivation for established and young investigators as well as trainees are also among the most important goals of this meeting.